BEAM
Price
$27.50
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
110 days until earnings call
TARS
Price
$46.51
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
123 days until earnings call
Ad is loading...

BEAM vs TARS

Header iconBEAM vs TARS Comparison
Open Charts BEAM vs TARSBanner chart's image
Beam Therapeutics
Price$27.50
Change-$0.00 (-0.00%)
Volume$822.51K
CapitalizationN/A
Tarsus Pharmaceuticals
Price$46.51
Change-$0.00 (-0.00%)
Volume$857.86K
CapitalizationN/A
BEAM vs TARS Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
TARS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BEAM vs. TARS commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongSell and TARS is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (BEAM: $27.50 vs. TARS: $46.50)
Brand notoriety: BEAM and TARS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 83% vs. TARS: 106%
Market capitalization -- BEAM: $2.31B vs. TARS: $1.77B
BEAM [@Biotechnology] is valued at $2.31B. TARS’s [@Biotechnology] market capitalization is $1.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileTARS’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • TARS’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than TARS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while TARS’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 4 bearish.
  • TARS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than TARS.

Price Growth

BEAM (@Biotechnology) experienced а +3.31% price change this week, while TARS (@Biotechnology) price change was -0.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.83%. For the same industry, the average monthly price growth was +3.51%, and the average quarterly price growth was +6.16%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 04, 2025.

TARS is expected to report earnings on Mar 17, 2025.

Industries' Descriptions

@Biotechnology (-1.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.18B) has a higher market cap than TARS($1.77B). TARS YTD gains are higher at: 129.630 vs. BEAM (1.029). TARS has higher annual earnings (EBITDA): -144.23M vs. BEAM (-162.88M). BEAM has more cash in the bank: 1.01B vs. TARS (324M). TARS has less debt than BEAM: TARS (72.2M) vs BEAM (165M). BEAM has higher revenues than TARS: BEAM (353M) vs TARS (83.4M).
BEAMTARSBEAM / TARS
Capitalization2.18B1.77B123%
EBITDA-162.88M-144.23M113%
Gain YTD1.029129.6301%
P/E RatioN/AN/A-
Revenue353M83.4M423%
Total Cash1.01B324M311%
Total Debt165M72.2M229%
TECHNICAL ANALYSIS
Technical Analysis
BEAMTARS
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 16 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
TARS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SUSIX14.41N/A
N/A
State Street Instl US Equity Inv
PJDAX20.06-0.01
-0.05%
PGIM Jennison Rising Dividend A
JVMSX31.66-0.06
-0.19%
JHancock Disciplined Value Mid Cap R2
IVINX37.35-0.22
-0.59%
Delaware Ivy Global Growth Fund Class A
TGVIX28.10-0.33
-1.16%
Thornburg International Equity I

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-1.57%
CRSP - BEAM
75%
Closely correlated
-1.85%
NTLA - BEAM
68%
Closely correlated
-3.24%
DNLI - BEAM
64%
Loosely correlated
-0.84%
EDIT - BEAM
64%
Loosely correlated
-3.58%
RXRX - BEAM
62%
Loosely correlated
-3.56%
More

TARS and

Correlation & Price change

A.I.dvisor indicates that over the last year, TARS has been loosely correlated with DNLI. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARS
1D Price
Change %
TARS100%
-2.25%
DNLI - TARS
35%
Loosely correlated
-0.84%
BEAM - TARS
35%
Loosely correlated
-1.57%
SPRY - TARS
34%
Loosely correlated
-15.23%
ADMA - TARS
33%
Loosely correlated
-1.40%
MDGL - TARS
33%
Loosely correlated
-7.05%
More